News - OxyDial Inc

Jan 23 2025

Bristol Myers Squibb, Texas Children’s Global HOPE, and Baylor College of Medicine, Launch Program to Address Sickle Cell Disease in Sub-Saharan Africa

The Bristol Myers Squibb Foundation, Texas Children’s Global Health Network HOPE, and Baylor College of Medicine Global Health have announced a new initiative to combat sickle cell disease in Sub-Saharan …

OxyDial

Jan 17 2025

Agios Secures EC Endorsement for Sickle Cell Therapy

Agios Pharmaceuticals has announced that the European Commission (EC) has granted orphan medicinal product designation to their oral therapy, mitapivat, for treating sickle cell disease (SCD). Already recognized with orphan …

OxyDial

Dec 23 2024

Novo Nordisk to Present Promising New Data on Sickle Cell Disease at ASH Annual Meeting

Novo Nordisk is set to share groundbreaking data from its HIBISCUS phase 2 trial at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego. This …

OxyDial

Nov 28 2024

AB Science Receives European Patent for Masitinib in Sickle Cell Disease Treatment

AB SCIENCE USA, LLC announced that it has received a notice of allowance from the European Patent Office for a patent covering the use of masitinib, an oral therapy in …

OxyDial

Nov 13 2024

KIND Gets FDA Orphan Drug Designation for Sickle Cell Disease Treatment

KINDPharmaceutical, a biotech company, announced that the FDA has granted Orphan Drug Designation to their drug AND017 for treating sickle cell disease. AND017 is being developed by KIND to treat …

OxyDial

Oct 29 2024

Agios Completes Enrollment for Sickle Cell Disease Trial

The Phase 3 RISE UP trial has marked a significant step forward in addressing sickle cell disease (SCD). @Agios Pharmaceuticals has completed enrollment for this pivotal study. The trial is …

OxyDial

Oct 22 2024

Zydus and ICMR Launch Trial for New Sickle Cell Disease Treatment

Zydus Group and Indian Council of Medical Research (ICMR) have announced a collaboration to begin testing a new medicine for sickle cell disease. They’re initiating a Phase 2 trial of …

OxyDial

Oct 4 2024

Mitem Pharma Acquires Worldwide Rights to Desferal from Novartis

In a strategic move within the hematology field, French pharmaceutical company MITEM Pharma has successfully acquired the global rights to Desferal (deferoxamine) from Novartis. Desferal, an essential medicine listed by …

OxyDial

Sep 27 2024

Luspatercept Outperforms Epoetin Alfa in Phase III COMMANDS Trial for MDS Anemia

The phase III COMMANDS trial has revealed a massive development in treating myelodysplastic syndromes (MDS). According to the primary analysis, Luspatercept, developed by Acceleron Pharma, demonstrated superior efficacy to epoetin …